154 related articles for article (PubMed ID: 1852896)
21. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
Sinzinger H; Rogatti W
Wien Klin Wochenschr; 1991; 103(18):558-65. PubMed ID: 1750223
[TBL] [Abstract][Full Text] [Related]
22. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
23. Plasma prostaglandin E1 concentrations and hemodynamics during intravenous infusions of prostaglandin E1 in humans and swine.
Awas JA; Soteriou MC; Drougas JG; Stokes KA; Roberts LJ; Pinson CW
Transplantation; 1996 Jun; 61(11):1624-9. PubMed ID: 8669108
[TBL] [Abstract][Full Text] [Related]
24. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
Thum J; Caspary L; Creutzig A; Alexander K
Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
[TBL] [Abstract][Full Text] [Related]
25. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H
Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
[TBL] [Abstract][Full Text] [Related]
26. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
Heidrich H
Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
[TBL] [Abstract][Full Text] [Related]
27. Prostaglandin E1 produces spasmolytic effects on histamine-induced bronchoconstriction in dogs.
Hashimoto Y; Hirota K; Ohtomo N; Sato T; Ishihara H; Matsuki A
Crit Care Med; 1999 Dec; 27(12):2755-9. PubMed ID: 10628622
[TBL] [Abstract][Full Text] [Related]
28. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
Weiss T; Eckstein H; Weiss C; Diehm C
Vasc Med; 1998; 3(3):171-5. PubMed ID: 9892509
[TBL] [Abstract][Full Text] [Related]
29. Iontophoretic application of prostaglandin E1 for improvement in peripheral microcirculation.
Saeki S; Yamamura K; Matsushita M; Nishikimi N; Sakurai T; Nimura Y
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):525-9. PubMed ID: 9799055
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome.
Cox JW; Andreadis NA; Bone RC; Maunder RJ; Pullen RH; Ursprung JJ; Vassar MJ
Am Rev Respir Dis; 1988 Jan; 137(1):5-12. PubMed ID: 3337471
[TBL] [Abstract][Full Text] [Related]
31. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of intravenously applied prostaglandin E1.
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
[TBL] [Abstract][Full Text] [Related]
33. Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1.
Weiss T; Fischer D; Hausmann D; Weiss C
Prostaglandins Leukot Essent Fatty Acids; 2002 Nov; 67(5):277-81. PubMed ID: 12445486
[TBL] [Abstract][Full Text] [Related]
34. Omega-hydroxylation of prostaglandin E1 in the isolated perfused lungs of pregnant rabbits.
Leithauser MT; Roerig DL; Winquist SM; Gee A; Okita RT; Masters BS
Prostaglandins; 1988 Dec; 36(6):819-33. PubMed ID: 3244833
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacologic concepts for clinical use of prostaglandin E1].
Schrör K
Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
[TBL] [Abstract][Full Text] [Related]
36. Biosynthesis of a novel prostaglandin, delta 17-PGE1, in the ram.
Oliw EH; Sprecher H; Hamberg M
Acta Physiol Scand; 1986 May; 127(1):45-9. PubMed ID: 3728046
[TBL] [Abstract][Full Text] [Related]
37. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
[TBL] [Abstract][Full Text] [Related]
38. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
39. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
40. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
